Last $0.50 USD
Change Today -0.02 / -3.85%
Volume 138.1K
NVIV On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

invivo therapeutics holdings (NVIV) Snapshot

Open
$0.52
Previous Close
$0.52
Day High
$0.54
Day Low
$0.49
52 Week High
02/27/14 - $2.67
52 Week Low
09/10/14 - $0.47
Market Cap
46.7M
Average Volume 10 Days
278.0K
EPS TTM
$-0.25
Shares Outstanding
93.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INVIVO THERAPEUTICS HOLDINGS (NVIV)

Related News

No related news articles were found.

invivo therapeutics holdings (NVIV) Related Businessweek News

No Related Businessweek News Found

invivo therapeutics holdings (NVIV) Details

Invivo Therapeutics Holdings Corp., a development stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injuries (SCI). The company is developing a biocompatible Neuro-Spinal Scaffold to treat acute SCI; and biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI. Its proprietary technologies incorporate intellectual property licensed under exclusive, worldwide license from Children’s Medical Center Corporation and the Massachusetts Institute of Technology, as well as intellectual property that has been developed internally in collaboration with advisors and partners. The company was founded in 2005 and is based in Cambridge, Massachusetts.

45 Employees
Last Reported Date: 03/17/14
Founded in 2005

invivo therapeutics holdings (NVIV) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: $1.0K
Compensation as of Fiscal Year 2013.

invivo therapeutics holdings (NVIV) Key Developments

The Rosen Law Firm Announces Filing of Securities Class Action against InVivo Therapeutics Holdings Corp

The Rosen Law Firm announced that a class action lawsuit has been filed on behalf of all purchasers of the securities of InVivo Therapeutics Holdings Corp. between April 5, 2013 and August 26, 2013, seeking remedies under the federal securities laws. According to the lawsuit, the company misstated and/or failed to disclose the true amount of time required to submit data to the FDA in the company's biopolymer scaffolding product. On August 27, 2013, the company admitted that its previously announced target date for completing the study and providing its data to the FDA would not be met due to condition established by the FDA. The lawsuit claims that when this adverse news entered the market the price of the company' stock dropped, damaging investors.

InVivo Therapeutics Holdings Corp. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 10:00 AM

InVivo Therapeutics Holdings Corp. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 10:00 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Mark D. Perrin, Chief Executive Officer, President and Director.

InVivo Therapeutics Holdings Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

InVivo Therapeutics Holdings Corp. reported earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of approximately $3,646,000, or $0.04 per diluted share, compared to a net loss of $14,286,000 or $0.20 per diluted share, for the quarter ended June 30, 2013. The 2014 results were impacted by two items. First, a gain in the derivative warrant liability of $1,127,000, and second, an unfavorable impact of $309,000 related to the realignment of resources completed in the quarter. The results for the quarter ended June 30, 2013 were adversely impacted by non-cash losses from the modification of warrants and derivatives of $9,187,000, reflecting changes in the fair market value of the derivative warrant liability. Exclusive of these items, for the quarter ended June 30, 2014 and 2013, earnings loss per diluted share was $0.05 and $0.07, respectively. For the six months, the company reported a net loss of approximately $8,749,000, or $0.11 per diluted share, compared to a net loss of $27,612,000 or $0.40 per diluted share, for the six months ended June 30, 2013. The 2014 results were impacted by two items. First, a gain in the derivative warrant liability of $1,127,000 and second, an unfavorable impact of $309,000 related to the realignment of resources completed in the second quarter. The results for the six months ended June 30, 2013 were adversely impacted by non-cash losses from modification of warrants and derivatives of $19,636,000, reflecting changes in the fair market value of the derivative warrant liability. Exclusive of these items, for the six months ended June 30, 2014 and 2013, earnings loss per diluted share was $0.12 and $0.12 respectively.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVIV:US $0.50 USD -0.02

NVIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVIV.
View Industry Companies
 

Industry Analysis

NVIV

Industry Average

Valuation NVIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INVIVO THERAPEUTICS HOLDINGS, please visit www.invivotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.